Q FEVER, DIAGNOSIS AND MANAGEMENT

In the other treatment-experienced trial (VIKING-3), one subject experienced SAEs considered related to dolutegravir which was a case of drug eruption with elevated ALT and hyperbilirubinemia. In the 60-day Safety Update Report, one subject had a suicide attempt that was taking dolutegravir for approximately one year at the time of the attempt. ................
................